^
Association details:
| Biomarker: | GNAQ mutation |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + elesclomol (STA-4783) (Apoptosis stimulant, Reactive oxygen species stimulant, HSP70 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma
Published date:
06/13/2022
Excerpt:
Furthermore, addition of binimetinib, a MEK inhibitor, to elesclomol increased its synthetic lethality to GNAQ/11-mutant UM cells, thereby overriding drug resistance. This effect was confirmed in an orthotopic xenograft model and in a patient-derived xenograft model of UM....Elesclomol may provide a new therapeutic path for selectively targeting malignant GNAQ/11-mutant UM.
DOI:
10.1038/s41388-022-02364-0
